跳转至内容
Merck
CN

SML0517

Amlexanox

≥98% (HPLC)

别名:

2-Amino-7-(1-methylethyl)-5-oxo-5H-[1]Benzopyrano[2,3-b]pyridine-3-carboxylic acid, AA 673, Amoxanox, CHX 3673

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C16H14N2O4
化学文摘社编号:
分子量:
298.29
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

SGRYPYWGNKJSDL-UHFFFAOYSA-N

SMILES string

CC(C)c1ccc2Oc3nc(N)c(cc3C(=O)c2c1)C(O)=O

InChI

1S/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H,1-2H3,(H2,17,18)(H,20,21)

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 10 mg/mL at warmed, clear

shipped in

wet ice

storage temp.

−20°C

Quality Level

Gene Information

General description

Amlexanox is an anti-allergic drug with anti-inflammatory properties.

Biochem/physiol Actions

Amlexanox elevates the amount of nonsense-containing mRNAs in treated cells and helps to generate full-length proteins effectively.
Amlexanox is an anti-allergy and anti-asthma drug that blocks histamine and leukotriene release from leukocytes and mast cells. Amlexanox has also been shown to inhibit cahaperone activity of Hsp90, and S100A13, which is involved in transport of proteins devoid of signal peptide sequences.
Amlexanox is an anti-allergy, anti-ulcer drug; S100A13 inhibitor.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

M Sugiura et al.
Contact dermatitis, 38(2), 65-67 (1998-03-20)
A 23-year-old woman developed allergic rhinitis in 1993. Her doctor prescribed for her Solfa (amlexanox 25 mg) and Lysozymen 90 (lysozyme chloride 90 mg) tablets. She took the tablets occasionally, whenever she developed allergic rhinitis. She noticed a macular erythema
Jie Liu et al.
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 102(4), 475-481 (2006-09-26)
The objectives of this study were to clinically determine the topical efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulcerations (MiRAU) in a Chinese cohort. A randomized, double-blind, vehicle-controlled, unparallel multicenter clinical trial
R W Barrons
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 58(1), 41-50 (2001-02-24)
The clinical features, etiology, and treatment of recurrent aphthous ulcers (RAU) are discussed. Aphthous ulcers are among the most common oral lesions in the general population, with a frequency of up to 25% and three-month recurrence rates as high as
Shannon M Reilly et al.
Nature medicine, 19(3), 313-321 (2013-02-12)
Emerging evidence suggests that inflammation provides a link between obesity and insulin resistance. The noncanonical IκB kinases IKK-ɛ and TANK-binding kinase 1 (TBK1) are induced in liver and fat by NF-κB activation upon high-fat diet feeding and in turn initiate
F Tarantini et al.
The Journal of biological chemistry, 276(7), 5147-5151 (2000-11-23)
Interleukin (IL)1alpha mediates proinflammatory events through its extracellular interaction with the IL1 type I receptor. However, IL1alpha does not contain a conventional signal peptide sequence that provides access to the endoplasmic reticulum-Golgi apparatus for secretion. Thus, we have studied the

商品

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持